1-4 of 4
Eider F Moreno Cortes, MD
Close
Sort by
Journal Articles

Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience

Jose V. Forero, MD, Paula A. Lengerke Diaz, MD, Eider F. Moreno Cortes, MD, Megan Melody, MD, Allison C. Rosenthal, D.O., Mohamed A. Kharfan-Dabaja, MDMBA, Januario E. Castro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-143168
Published: 2020
Journal Articles

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Paula A. Lengerke Diaz, MD, Michael Y. Choi, MD, Eider F. Moreno Cortes, MD, Jose V. Forero, MD, Juliana Velez-Lujan, PhD, Carlos I. Amaya-Chanaga, MD, Thomas Kipps, MDPhD, Januario E. Castro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-143473
Published: 2020
Journal Articles

Chimeric Antigen Receptor T Cell Therapy Pipeline at a Glance: A Retrospective and Systematic Analysis from Clinicaltrials.Gov

Eider F Moreno Cortes, MD, Caleb K Stein, PhD, Paula A Lengerke Diaz, MD, Cesar A Ramirez-Segura, BS, PhD, Januario E. Castro, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5629.
https://doi.org/10.1182/blood-2019-132273
Published: 2019
Journal Articles

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Juliana Velez Lujan, BS,PhD, Chaja Jacobs, MD, Paula A Lengerke Diaz, MD, Eider F Moreno-Cortes, MD, Cesar A Ramirez-Segura, BS, PhD, Michael Y. Choi, MD, Colin McCarthy, BS, Alaina Heinen, BS, Carlos Amaya-Chanaga, MD, Thomas J. Kipps, MD PhD, Januario E Castro, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1864.
https://doi.org/10.1182/blood-2018-99-119523
Published: 2018